Search alternatives:
somatic decrease » small decrease (Expand Search)
Showing 521 - 540 results of 553 for search '(( aromatic decrease ) OR ( ((somatic decrease) OR (dramatic decrease)) ))', query time: 0.26s Refine Results
  1. 521
    Image 11_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 11_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  2. 522
    Table 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx

    Table 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.docx by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  3. 523
    Image 3_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif

    Image 3_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  4. 524
    Image 6_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 6_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  5. 525
    Image 10_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 10_The CYP4/20-HETE/GPR75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  6. 526
    Image 3_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif

    Image 3_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tif by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  7. 527
    Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 6_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  8. 528
    Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 7_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  9. 529
    Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 5_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  10. 530
    Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 9_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  11. 531
    Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 11_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  12. 532
    Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 1_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  13. 533
    Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1

    Edaravone inhibits neuronal ferroptosis and alleviates acute Central nervous system injury induced by diquat <i>via</i> enhancement of METTL14-mediated m6A methylation of Aldh1l1 by Liaozhang Wu (8371008)

    Published 2025
    “…Mitophagy inhibitor Mdivi-1 reversed the induction of ferroptosis effects of diquat via decreased Fe2+ content and increased Ca2+ level. knockdown of METTL14 reversed the therapeutic effect of Eda on diquat-induced injury. …”
    Save to List
    Saved in:
  14. 534
    Image 4_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 4_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  15. 535
    Image 8_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 8_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  16. 536
    Image 10_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 10_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  17. 537
    Image 2_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff

    Image 2_The CYP4/20-HETE/GRP75 axis in the progression metabolic dysfunction-associated steatosis liver disease (MASLD) to chronic liver disease.tiff by James P. Hardwick (20634155)

    Published 2025
    “…These results were confirmed by increased P4504A11 protein levels and decreased P4504F2 protein levels during the development and progression of MASLD. …”
    Save to List
    Saved in:
  18. 538
    Table13_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table13_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  19. 539
    Table6_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table6_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:
  20. 540
    Table4_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls

    Table4_MiR-29b-3p Inhibits Migration and Invasion of Papillary Thyroid Carcinoma by Downregulating COL1A1 and COL5A1.xls by Congjun Wang (1267932)

    Published 2025
    “…Finally, miR-29b-3p agomir treatment dramatically inhibited Xenograft tumor growth in the animal model.…”
    Save to List
    Saved in:

Search Tools: